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ABSTRACT 
CONTEXT AND OBJECTIVE: Autism spectrum disorders (ASDs) include autistic disorder, Asperger’s disor-
der and pervasive developmental disorder. The manifestations of ASDs can have an important impact on 
learning and social functioning that may persist during adulthood. The aim here was to summarize the 
evidence from Cochrane systematic reviews on interventions for ASDs. 
DESIGN AND SETTING: Review of systematic reviews, conducted within the Discipline of Evidence-Based 
Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo. 
METHODS: We included and summarized the results from Cochrane systematic reviews on interventions 
for ASDs. 
RESULTS: Seventeen reviews were included. These found weak evidence of benefits from acupuncture, glu-
ten and casein-free diets, early intensive behavioral interventions, music therapy, parent-mediated early 
interventions, social skill groups, Theory of Mind cognitive model, aripiprazole, risperidone, tricyclic anti-
depressants and selective serotonin reuptake inhibitors (SSRI); this last only for adults. No benefits were 
found for sound therapies, chelating agents, hyperbaric oxygen therapy, omega-3, secretin, vitamin B6/
magnesium and SSRI for children.
CONCLUSION: Acupuncture, gluten and casein-free diets, early intensive behavioral interventions, music 
therapy, parent-mediated early interventions, social skill groups and the Theory of Mind cognitive model 
seem to have benefits for patients with autism spectrum disorders (very low to low-quality evidence). 
Aripiprazole, risperidone, tricyclic antidepressants and SSRI (this last only for adults) also showed some 
benefits, although associated with higher risk of adverse events. Experimental studies to confirm a link 
between probable therapies and the disease, and then high-quality long-term clinical trials, are needed.
RESUMO 
CONTEXTO E OBJETIVO: Os transtornos do espectro autista (TEA) incluem autismo, doença de Asperger 
e transtorno global do desenvolvimento. As manifestações dos TEA podem ter importante impacto na 
aprendizagem e funcionamento social, que pode persistir durante a fase adulta. O objetivo foi resumir as 
evidências de revisões sistemáticas Cochrane sobre intervenções para TEA.
TIPO DE ESTUDO E LOCAL: Revisão de revisões sistemáticas conduzida na Disciplina de Medicina Basea-
da em Evidências da Escola Paulista de Medicina, Universidade Federal de São Paulo.
MÉTODOS: Nós incluímos e resumimos os resultados de revisões sistemáticas Cochrane sobre interven-
ções para TEA. 
RESULTADOS: Foram incluídas 17 revisões que encontraram evidências fracas de benefícios da acupun-
tura, dietas isentas de glúten e caseína, intervenção comportamental intensiva precoce, musicoterapia, 
intervenção precoce mediada pelos pais, grupos de habilidades sociais, modelo cognitivo de Teoria da 
Mente, aripiprazol, risperidona, antidepressivos tricíclicos, inibidores seletivos da recaptação da serotonina 
(ISRS); o último apenas para adultos. Nenhum benefício foi encontrado com terapias sonoras, agentes 
quelantes, oxigenoterapia hiperbárica, ômega-3, secretina, vitamina B6/magnésio e ISRS para crianças.
CONCLUSÃO: Acupuntura, dietas sem glúten e caseína, intervenção comportamental intensiva precoce, 
musicoterapia, intervenção precoce mediada pelos pais, grupos de habilidades sociais e modelo cognitivo 
de Teoria da Mente parecem ter benefícios para pacientes com TEA (evidência de qualidade muito baixa 
a baixa). Aripiprazol, risperidona, antidepressivos tricíclicos e ISRS (o último apenas para adultos) também 
apresentam algum benefício, embora estejam associados a maior risco de eventos adversos. Estudos ex-
perimentais confirmando a relação entre prováveis terapias e a doença, e então ensaios clínicos de alta 
qualidade e de longo seguimento, são necessários.
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INTRODUCTION
Autism spectrum disorders (ASDs) have an estimated preva-
lence ranging from 3.3 to 116 children per 10,000 and it is widely 
accepted that autism affects approximately 1% of children world-
wide.1 This may reflect increased access to diagnosis, concern 
among healthcare professionals and parents, more sensitive diag-
nostic criteria and/or a true increase in prevalence.2
ASDs include autistic disorder, Asperger’s disorder and perva-
sive developmental disorder. Patients with these conditions present 
deficits in communication, social interaction and cognitive function; 
problems with feeding; hypo or hypersensitivity; and, sometimes, 
self-harmful behavior.3 With greater severity of ASDs, activities 
of daily living are limited and the impairments of ASDs can have 
an important impact on learning and social functioning that may 
persist during adulthood.4
Healthcare and social care for people with ASDs is frequently 
complex, since they are more likely to have mental health comor-
bidities and suicidal ideation.5 Assessments need to be multidis-
ciplinary and developmental, and early detection is determinant. 
Therapeutic interventions need to be personalized, focusing on the 
specific clinical features presented by each patient.6
Individual or parent-based psychosocial interventions are fre-
quently used in clinical practice, with the aim of improving clinical 
features relating to communication, cognition, behavior and rela-
tionships, for instance. Pharmacological therapy is an option for 
mental health comorbidities. New therapeutic approaches include 
genetic and pharmacological strategies for reducing synthesis of spe-
cific proteins and inhibiting pleiotropic growth factors.7 Concerning 
the time for starting the treatment, randomized controlled trials 
have added new evidence that, for many children aged up to three 
years, early intervention can improve outcomes, thus increasing the 
potential benefits of early diagnosis facilitated by early screening.8,9 
Despite recent advances in this area, the evidence regarding autism 
remains limited and this condition continues to be a challenge for 
researchers, healthcare professionals, patients, parents and caregivers.
OBJECTIVES 
To map out and summarize all Cochrane systematic reviews on 
interventions for autism spectrum disorders, and present the 
results on the basis of the quality of the evidence.
METHODS 
Design 
Review of Cochrane systematic reviews on interventions for ASD. 
Setting
Discipline of Evidence-Based Medicine, Escola Paulista de 
Medicina, Universidade Federal de São Paulo (UNIFESP), Brazil. 
Criteria for including reviews 
Types of study 
We included completed Cochrane systematic reviews, with no 
restriction regarding date of publication. Protocols for systematic 
reviews and reviews signaled as “withdrawn” in the Cochrane 
Database of Systematic Reviews (CDSR) were not considered. 
We included only the latest version of each review. 
Types of participants 
Individuals with ASD.
Types of interventions 
All types of interventions (pharmacological and non-pharmaco-
logical) aiming to treat ASD. 
Type of outcomes 
Clinical and laboratory outcomes were considered, as presented 
by the systematic reviews.
Searching for reviews 
We conducted systematic searches in the Cochrane Database of 
Systematic Reviews (CDSR) (via Wiley) using a sensitive search 
strategy (Table 1). 
Selecting reviews 
Three reviewers evaluated the titles and abstracts of records that 
had initially been retrieved on the basis of the inclusion crite-
ria. The full texts of records with the potential for inclusion were 
read to confirm whether they should be included (reasons for 
exclusions were recorded and presented). Divergences between 
reviewers were resolved through reaching a consensus. 
Presenting the results
We used a narrative structure (qualitative synthesis) to present 
the results from the systematic reviews included. 
RESULTS 
Search results
The initial search retrieved 24 reviews. From these, we excluded six 
reviews addressing other clinical situations (X fragile syndrome, 
Table 1. Search strategy and results from Cochrane Database 
of Systematic Reviews (conducted on November 22, 2016)
#1
“autism spectrum disorder” in Title, Abstract, 
Keywords
#2 “autism” in Title, Abstract, Keywords
#3 “Asperger” in Title, Abstract, Keywords
#1 OR #2 OR #3 (in Cochrane Reviews)
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prematurity and attention deficit hyperactivity disorder) and one 
that was a previous version of a review that we included. Thus, we 
included 17 systematic reviews.4,10-25
Results from systematic reviews
A summary of each systematic review is presented narratively 
below. In addition, Table 24,10-25 presents the issues addressed, 
the main findings from each systematic review and the quality 
of the evidence (based on the GRADE approach).26
1. Acupuncture
The review4 considered randomized controlled trials (RCTs) 
and quasi-randomized controlled trials and included 10 studies 
(from low to high methodological quality) on 390 children aged 
from 3 to 18 years who presented ASDs and received acupunc-
ture for periods ranging from four weeks to nine months. The fol-
lowing results were found:
• Needle acupuncture (by means of manual or electrical stim-
ulation) versus sham: no difference in core autistic features. 
On the Ritvo-Freeman Real Life Rating Scale (RFRLRS): mean 
difference (MD) = 0.09; 95% confidence interval (CI) = -0.03 
to 0.21; P = 0.16. Acupuncture seemed to result in better lan-
guage comprehension, cognition, selfcare and social function-
ing, and a higher probability of improvement in overall func-
tioning greater than or equal to 25%.
• Needle acupuncture (by means of manual or electrical stimu-
lation) versus no treatment: acupuncture seemed to improve 
autistic features, speech, cognition, overall functioning, self-
care, sensory functioning, imitation, repetitive behavior and 
physical health. 
• Acupressure versus no treatment: acupressure might result in 
improvement in overall functioning, communication attitude, 
non-verbal communication and matching, and in language 
and social interaction.
Most of the favorable outcomes were observed only in a single 
study and few outcomes were supported by pooled results from 
more than one study. The majority of the effect size estimates for 
the significant outcomes had imprecisions with a wide confidence 
interval. These limitations mean that the significant result was not 
sufficiently robust to enable a reliable conclusion. 
Therefore, the authors concluded that the current evidence did 
not support use of acupuncture for treating ASDs. For further details, 
the original abstract can be consulted, available from: http://onlineli-
brary.wiley.com/doi/10.1002/14651858.CD007849.pub2/abstract.
2. Aripiprazole 
Antipsychotics have been used as medications for ASD-related 
irritability. The review10 included three RCTs on children and 
adolescents (aged from 9 to 17 years): two were short-term stud-
ies (eight weeks) on the effects of aripiprazole on behavioral 
problems among 316 children/adolescents; one was a longer-
term study (up to 16 weeks) in which 85 children/adolescents 
whose symptoms initially improved through aripiprazole were 
withdrawn from the medication to assess whether their behav-
ioral problems would recur. All three RCTs were supported by 
Bristol-Myers Squibb (Princeton, NJ, United States) and Otsuka 
Pharmaceutical Company, Ltd. (Tokyo, Japan), and had edito-
rial support from Ogilvy Healthworld Medical Education and 
Bristol-Myers Squibb. The results from a meta-analysis showed 
that there was an improvement favoring aripiprazole, in compar-
ison with placebo, for the following outcomes:
• Aberrant Behavior Checklist (ABC) - irritability subscale (MD 
= -6.17 points; 95% CI = -9.07 to -3.26; two RCTs; 308 partici-
pants; moderate-quality evidence);
• ABC hyperactivity subscale (MD = -7.93 points; 95% CI = 
-10.98 to -4.88; two RCTs; 308 participants, moderate-quality 
evidence);
• ABC stereotypy subscale (MD = -2.66 points; 95% CI = -3.55 to 
-1.77; two RCTs; 308 participants, moderate-quality evidence).
In terms of side effects, aripiprazole was associated with greater 
increase in weight (MD = 1.13 kg; 95% CI = 0.71 to 1.54; two RCTs; 
308 participants; moderate-quality evidence), higher risk of seda-
tion (risk ratio [RR] = 4.28; 95% CI = 1.58 to 11.60; two RCTs; 
313 participants; moderate-quality evidence) and tremor (RR = 
10.26; 95% CI = 1.37 to 76.63; two RCTs; 313 participants; moder-
ate-quality evidence). The discontinuation RCT study showed no 
difference in relapse rate, with regard to symptoms of irritability 
(hazard ratio [HR] = 0.57; 95% CI = 0.28 to 1.12; 85 participants; 
low-quality evidence). 
The authors concluded that aripiprazole might be effective as 
a short-term intervention for some behavioral aspects of ASDs 
among children/adolescents. However, they stated that notable 
side effects, including weight gain, sedation, drooling and tremor, 
needed to be considered. For further details, the original abstract 
can be consulted, available from: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD009043.pub3/abstract.
3. Auditory integration training and other sound therapies
Auditory integration therapies (including Tomatis therapy and 
Samonas sound therapy) are techniques for improving abnormal 
sound sensitivity in individuals with behavioral disorders including 
ASDs. The review11 identified six RCTs that used auditory integra-
tion therapy and one that used Tomatis therapy (182 participants 
aged three to 39 years). Meta-analysis was not possible due to the 
huge heterogeneity among the RCTs or the reports of data in unus-
able forms. Three RCTs did not show any benefit from auditory 
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Intervention Details of intervention Results regarding effectiveness and safety 
Quality of evidence 
(GRADE approach)*
Acupuncture4
Manual or electrical 
acupuncture (four weeks to 
nine months) versus sham or 
no intervention
Acupuncture seemed to result in better language comprehension, 
cognition, selfcare, social functioning and overall functioning.
Acupressure seemed to improve some autistic features, speech, 
cognition, overall functioning, self-care, sensory functioning, imitation, 
repetitive behavior, physical health, communication attitude, nonverbal 
communication and matching, and language and social interaction.
Very low
Aripiprazole10
Aripiprazole 5, 10 or 15 mg/
day for eight weeks
Aripiprazole can be effective over short term for some behavioral 
aspects of ASDs in children/adolescents.
Weight gain, sedation, drooling and tremor were more frequent with 
aripiprazole. 
Aripiprazole discontinuation was not associated with lower relapse rates 
(irritability symptoms)
Moderate to low
Auditory integration 
training and other 
sound therapies11
Auditory integration training 
or Tomatis
No evidence suggesting benefits Very low
Chelating agents12
Multiple doses of oral 
dimercaptosuccinic acid for 
up to six months for children 
with ASDs who excrete high 
levels of heavy metals 
No evidence suggesting benefits Very low
Early intensive 
behavioral 
intervention13
Early intensive behavioral 
intervention over a period of 
14 months to 36 months
Evidence from non-randomized trials suggesting benefits for adaptive 
behavior, intelligence quotient, expressive language, receptive 
language, daily communication skills, socialization and daily living skills
Low
Gluten and casein-
free diets14
Diet for 12 weeks or 12 
months
Evidence suggesting benefits for overall autistic traits and overall ability 
to communicate and interact
Very low
Hyperbaric oxygen 
therapy15 
Hyperbaric oxygen therapy 
(pressure of 1.5 ATA with 
100% oxygen), 20 one-hour 
sessions held on weekdays 
over 10 weeks
Evidence suggesting no improvement in social interaction and 
communication, behavioral problems, communication and linguistic 
abilities, or cognitive function.
More adverse events in hyperbaric oxygen group.
Low
Music therapy16
Music therapy for one week to 
seven months
Evidence suggesting benefits for: social interaction within the therapy 
context, general social interaction outside therapy context, nonverbal 
communicative skills within the therapy context, verbal communicative 
skills, initiating behavior, social-emotional reciprocity, social adaptation, 
joy and quality of parent-child relationships
No benefits regarding nonverbal communicative skills outside of the 
therapy context 
None of the studies reported adverse events. 
Low to moderate
Omega-3 fatty 
acids17
Capsule or paste, at doses 
ranging from 1.3 g/day (0.7 g 
of eicosapentaenoic acid and 
0.46 g of docosahexaenoic
acid) to 1.5 g/day (0.84 g of 
eicosapentaenoic acid
and 0.7 g of docosahexaenoic 
acid), for six to 12 weeks.
No benefits for social interaction, communication, stereotypy or 
hyperactivity
Low
Parent-mediated 
early intervention18
Home-based and/or center 
or clinic-based interventions, 
delivered on a one-to-one 
basis or to groups of parents 
or self-training from a manual 
and videotapes. 
No benefit for most of the primary outcomes (language and 
communication, child initiations in observed parent-child interaction, 
child’s adaptive behavior and parents’ stress). 
Strong and statistically significant benefits for shared attention and 
parent synchrony.
Evidence suggestive of improvement in child vocabulary 
comprehension, and reduction in the severity of autism characteristics.
Low
Table 2. Characteristics and main results from systematic reviews included 
Continue...
COCHRANE HIGHLIGHTS | Lyra L, Rizzo LE, Sunahara CS, Pachito DV, Latorraca COC, Martimbianco ALC, Riera R
196     Sao Paulo Med J. 2017; 135(2):192-201
Intervention Details of intervention Results regarding effectiveness and safety 
Quality of evidence 
(GRADE approach)*
Risperidone19
Risperidone (2.5 mg to 
10 mg/day) for 8 to 12 weeks.
Evidence suggesting benefits for irritability, repetition and social 
withdrawal. 
Higher risk of adverse events, especially weight gain.
Not assessed
Secretin 
(intravenous)20
Porcine or synthetic human 
secretin in single or repeated 
doses, ranging from 2 IU/kg, 
synthetic secretin in a single 
dose of 4 IU/kg dose.
No benefits for core features of ASDs Not assessed
Selective serotonin 
reuptake inhibitors21
• Fluoxetine (10 to 80 mg/
day for 8 to 12 weeks)
• Fluvoxamine (up to 
300 mg/day for 9 to 
12 weeks)
• Fenfluramine (twice-daily 
divided dose totaling 
1.5 mg/kg, for 3 months) 
• Citalopram (up to 
30 mg/day)
No evidence of benefits for children and limited evidence for adults. Not assessed
Social skill groups22
One to 25 sessions per week, 
lasting 60 to 90 min, for 5 to 
20 weeks.
Evidence suggesting benefits for overall social competence, friendship 
quality and loneliness.
No benefit for emotional recognition, social communication relating to 
understanding idioms, or child or parental depression.
Low
Theory of Mind 
cognitive model23
Theory of Mind cognitive 
models delivered by computer 
program, specially-designed 
cartoons, one-to-one 
therapist-led intervention, 
teacher-training in classroom, 
for two weeks to six months.
Evidence suggesting benefits for communication based on individual, 
social interaction and general communication.
Low to very low
Tricyclic 
antidepressants24
Clomipramine or tianeptine 
for 5 to 7 weeks (no 
specified doses)
Tianeptine could be effective over short term for reducing irritability, 
hyperactivity, inadequate eye contact and inappropriate speech 
(according to parents’ assessment, but clinician ratings did not confirm 
these findings)
Tianeptine was associated with significant adverse effects, including 
drowsiness and reduced activity levels.
Clomipramine could be effective for improving autistic symptoms, 
irritability and obsessive-compulsive disorder symptoms.
Not assessed
Vitamin B6 plus 
magnesium25
Vitamin B6 30 mg/kg/day (up 
to 1 g) and magnesium 
10 mg/kg/day (up to 
350 mg/day)
No benefits for social interaction, communication, compulsivity, 
impulsivity, or hyperactivity.
Not assessed
Table 2. Continuation
integration therapy over control interventions. Three RCTs reported 
improvements from auditory integration therapy on the Aberrant 
Behavior Checklist, after three months, but they used a total score 
rather than subgroup scores, which is questionable. The study 
addressing Tomatis therapy did not find any difference between the 
treatment and control conditions regarding language. 
The authors concluded that, considering the methodologi-
cal limitations of the existing RCTs, no evidence supporting the 
use of auditory integration therapy or other sound therapies was 
available up to that time. For further details, the original abstract 
can be consulted, available from: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD003681.pub3/abstract.
4. Chelating agents for autism spectrum disorders (ASDs)
It has been suggested that the severity of autism spectrum dis-
order (ASD) symptoms is associated with the levels of serum or 
ASD = autism spectrum disorders; *GRADE = Grading of Recommendations Assessment, Development and Evaluation. Tool used for assessing the quality of the 
body of the current evidence. High quality: low probability that further studies will change the confidence regarding the existing evidence. Moderate quality: 
some probability that further studies will change the confidence regarding the existing evidence. Low quality: high probability that further studies will change 
the confidence regarding the existing evidence. Very low quality: there is much uncertainty about the information, precluding any valid interpretation.26
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stored toxic metals, and that chelating agents improve symptoms. 
The review12 aimed to assess the effects of these agents on ASDs 
and included one randomized clinical trial (RCT) with 49 chil-
dren. This RCT compared multiple doses of oral dimercaptosuc-
cinic acid (DMSA), for up to six months versus placebo among 
children who excreted high levels of heavy metals. 
The authors concluded that there was no evidence to suggest 
that multiple rounds of oral DMSA had any effect on ASD symp-
toms. Considering previous reports of serious adverse events, 
including hypocalcemia, renal impairment and reported death, 
they stated that the risks involved in chelation to treat ASDs cur-
rently outweighed the benefits. Evidence supporting a causal rela-
tion between heavy metals and autism would be needed before fur-
ther trials were conducted. For further details, the original abstract 
can be consulted, available from: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD010766.pub2/abstract.
5. Early intensive behavioral intervention
Early intensive behavioral intervention (EIBI) is based on the 
principles of applied behavioral analysis on interventions deliv-
ered over many years for 20 to 40 hours per week. For the 
review,13 the participants needed to have been less than six years 
of age at treatment onset and to have been assigned to their study 
condition prior to starting treatment. This review included one 
RCT and four non-randomized trials (203 participants) that used 
a treatment-as-usual comparison group. Positive effects favoring 
EIBI were found for all the following outcomes: 
• Adaptive behavior (standardized mean difference using Hedges 
g = 0.69; 95% CI = 0.38 to 1.01; P < 0.0001); 
• Intelligence quotient, IQ (g = 0.76; 95% CI = 0.40 to 1.11; 
P < 0.0001); 
• Expressive language (g = 0.50; 95% CI = 0.05 to 0.95; P = 0.03);
• Receptive language (g = 0.57; 95% CI = 0.20 to 0.94; P = 0.03);
• Daily communication skills (g = 0.74; 95% CI = 0.30 to 1.18; 
P = 0.0009); 
• Socialization (g = 0.42; 95% CI = 0.11 to 0.73; P = 0.0008);
• Daily living skills (g = 0.55; 95% CI = 0.24 to 0.87; P = 0.0005). 
The authors concluded that there was some evidence that 
EIBI was effective for children with ASDs. However, they consid-
ered that the current state of the evidence was limited because the 
data came from non-randomized studies. For further details, the 
original abstract can be consulted, available from:  http://onlineli-
brary.wiley.com/doi/10.1002/14651858.CD009260.pub2/abstract.
6. Gluten and casein-free diets 
It has been hypothesized that peptides from gluten and casein 
may participate in the origins of autism and that that physiol-
ogy and psychology of autism might be explained in terms of 
excessive opioid activity linked to these peptides. The review14 
included two small RCTs (35 participants) assessing the effects of 
gluten and casein-free diets for ASDs. No meta-analysis was pos-
sible, due to different outcome measurements. There were signifi-
cant treatment effects favoring the dietary intervention for over-
all autistic traits (MD = -5.60; 95% CI = -9.02 to -2.18; P = 0.001) 
and the overall ability to communicate and interact (MD = 1.70; 
95% CI = 0.50 to 2.90). No adverse events were reported. 
The authors concluded that, despite the high rates of use of gluten 
and/or casein-free diets for children with ASDs, the current evidence 
was not robust enough to support these practices. For further details, 
the original abstract can be consulted, available from: http://onlineli-
brary.wiley.com/doi/10.1002/14651858.CD003498.pub3/abstract.
7. Hyperbaric oxygen therapy 
It has been hypothesized that hyperbaric oxygen therapy might 
reduce the biochemical dysfunction and clinical symptoms of 
ASDs. The review15 included one RCT (60 children) comparing 
hyperbaric oxygen therapy and sham treatment, and the results 
showed that there were no improvements in social interaction 
and communication, behavioral problems, communication 
and linguistic abilities, or cognitive function. There were more 
adverse events (odds ratio [OR)] = 3.87; 95% CI = 1.53 to 9.82) 
and more children who experienced adverse events (OR = 4.40; 
95% CI = 1.33 to 14.48) in the hyperbaric oxygen group. 
The authors concluded that up to that time, there was no evi-
dence that hyperbaric oxygen therapy improved the core symptoms 
and associated symptoms of ASDs. They stated that it was important 
to consider that adverse events could occur. For further details, the 
original abstract can be consulted, available from: http://onlineli-
brary.wiley.com/doi/10.1002/14651858.CD010922.pub2/abstract.
8. Music therapy
The review16 is an updated version of a review published in 
2006 that aimed to assess the effects of music therapy for ASD. 
Ten RCTs (165 participants) examined the short and medium-
term effects of music therapy over periods of one week to seven 
months for children with ASDs. Music therapy was better than 
“placebo” therapy or the usual care for the following outcomes:
• Social interaction within the therapy context (standard mean 
difference [SMD] = 1.06; 95% CI = 0.02 to 2.10; one RCT; 
10 participants);
• General social interaction outside of therapy context (SMD = 
0.71; 95% CI = 0.18 to 1.25; three RCTs; 57 participants; mod-
erate-quality evidence);
• Nonverbal communicative skills within the therapy context 
(SMD = 0.57; 95% CI = 0.29 to 0.85; three RCTs; 30 participants);
• Verbal communicative skills (SMD = 0.33; 95% CI = 0.16 to 
0.49; six RCTs; 139 participants);
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• Initiating behavior (SMD = 0.73; 95% CI = 0.36 to 1.11; three 
RCTs; 22 participants; moderate-quality evidence);
• Social-emotional reciprocity (SMD = 2.28; 95% CI = 0.73 to 
3.83; one RCT; 10 participants; low-quality evidence); 
• Social adaptation (SMD = 0.41; 95% CI = 0.21 to 0.60; four 
RCTs; 26 participants);
• Joy (SMD = 0.96; 95% CI = 0.04 to 1.88; one RCT; 10 partici-
pants); and
• Quality of parent-child relationships (SMD = 0.82; 95% CI = 0.13 
to 1.52; two RCTs; 33 participants; moderate-quality evidence).
There was no difference in nonverbal communicative skills out-
side of the therapy context (SMD = 0.48; 95% CI = -0.02 to 0.98; 
three RCTs; 57 participants; low-quality evidence). None  of 
the studies reported any adverse events. For further details, 
the original abstract can be consulted, available from: http://
onlinelibrary.wiley.com/doi/10.1002/14651858.CD004381.
pub3/abstract.
9. Omega-3 fatty acid supplementation
The review17 included two RCTs (37 children) comparing 
omega-3 fatty acid supplementation versus placebo. No evi-
dence was found that omega-3 supplements had any effect on 
social interaction (MD = 0.82; 95% CI = -2.84 to 4.48), commu-
nication (MD = 0.62; 95% CI = -0.89 to 2.14), stereotypy (MD = 
0.77; 95% CI = -0.69 to 2.22) or hyperactivity (MD = 3.46, 95% 
CI = -0.79 to 7.70). 
The authors concluded that, up to that time, there was no high-
quality evidence that omega-3 fatty acid supplementation was 
effective for children with ASDs. For further details, the original 
abstract can be consulted, available from: http://onlinelibrary.wiley.
com/doi/10.1002/14651858.CD007992.pub2/abstract.
10. Parent-mediated early intervention
Approaches that help parents develop strategies for interactions 
and management of behavior can be useful in cases of ASDs. 
The review18 included 17 RCTs on 919 children with ASDs. The 
following results were found:
• No benefit for most of the primary outcomes (language and 
communication, child initiations in observed parent-child 
interaction, child’s adaptive behavior and parents’ stress); 
• Strong and statistically significant benefits for patterns of 
parent-child interaction: shared attention (SMD = 0.41; 95% 
CI = 0.14 to 0.68) and parent synchrony (SMD = 0.90; 95% 
CI = 0.56 to 1.23); 
• Evidence suggestive of improvement of child vocabulary com-
prehension reported by parents (MD = 36.26; 95% CI = 1.31 
to 71.20) and reduction in the severity of children’s autism 
characteristics (SMD = -0.30; 95% CI = -0.52 to -0.08).
For further details, the original abstract can be consulted, avail-
able from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD009774.pub2/abstract.
11. Risperidone
The review19 included three RCTs (211 adults or children) com-
paring risperidone (2.5 mg to 10 mg/day) with placebo over 
periods of eight to 12 weeks. Some benefits were found regard-
ing irritability, repetition and social withdrawal. However, these 
needed to be considered in relation to the adverse events, espe-
cially weight gain. 
The authors concluded that risperidone might be beneficial 
in relation to some features of autism, but that the evidence was 
limited because the existing studies had small sample sizes with 
short follow-ups, and because of the lack of a single standardized 
outcome measurement. For further details, the original abstract 
can be consulted, available from: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD005040.pub2/abstract.
12. Secretin
Secretin, a gastrointestinal hormone, has been suggested as 
an effective treatment for ASDs based on anecdotal evidence. 
The review20 included 16 heterogeneous RCTs (two of these were 
conducted by Repligen, a pharmaceutical company) in which 
over 900 children were recruited to receive intravenous secre-
tin (porcine or synthetic, in single or multiple doses) or placebo. 
Twenty-five established standardized outcome measurements 
assessing communication, behavior, visuospatial skills, effects 
and adverse events were reported.
The authors concluded that there was no evidence that secretin 
was effective and that therefore currently it could not be recom-
mended and should not be administered as a treatment for ASDs. 
They stated that further RCTs would only be justifiable if there was 
any new high-quality replicable scientific evidence proving a link 
between secretin and ASDs. For further details, the original abstract 
can be consulted, available from: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD003495.pub3/abstract.
13. Selective serotonin reuptake inhibitors (SSRIs)
The review21 included nine heterogeneous RCTs (320 adults or 
children) assessing fluoxetine (three RCTs), fluvoxamine (two 
RCTs), fenfluramine (two RCTs) and citalopram (two RCTs). 
Varying inclusion criteria were used with regard to diagnostic 
criteria and the participants’ intelligence quotient. Due to hetero-
geneity, the data were unsuitable for meta-analysis, except for one 
outcome (proportional improvement). The results did not show 
any evidence of positive effects from citalopram for children 
with ASDs (one high-quality RCT). Three small RCTs on adults 
showed positive outcomes for clinical global impression (CGI) 
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and obsessive-compulsive behavior (OCB); one RCT showed 
improvements in aggression; and another in relation to anxiety. 
The authors concluded that there was no evidence of effects 
from SSRIs on children and that the evidence relating to adults was 
limited due to the small size of the studies, with unclear risk of bias. 
For further details, the original abstract can be consulted, avail-
able from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD004677.pub3/abstract.
14. Social skill groups
Major difficulties in social interactions have been found to be a 
defining feature of individuals with ASDs. The review22 included 
five RCTs (196 participants aged 6 to 21 years). The results 
showed that social skill groups improved overall social compe-
tence (SMD = 0.47; 95% CI = 0.16 to 0.78; P = 0.003), friendship 
quality (SMD = 0.41; 95% CI = 0.02 to 0.81; P = 0.04) and loneli-
ness (SMD = -0.66; 95% CI -1.15 to -0.17; one RCT). No differ-
ences were found regarding emotional recognition (SMD = 0.34; 
95% CI = -0.20 to 0.88; two RCTs), social communication in rela-
tion to understanding idioms (SMD = 0.05; 95% CI = -0.63 to 
0.72; one RCT) or child or parental depression. No adverse events 
were reported. Given the nature of the intervention and the out-
come measurements selected, the risks of performance and 
detection bias were high. There was only limited external validity 
for these results, since all the RCTs were conducted in the United 
States, focusing mainly on children aged 7 to 12, and the partici-
pants were all of average or above average intelligence. 
The authors concluded that there was some evidence that social 
skill groups might improve social competence for some children 
and adolescents with ASDs. They stated that further research was 
needed in order to reach conclusions that would be more robust, 
especially with regard to improvements in quality of life. For fur-
ther details, the original abstract can be consulted, available from: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008511.
pub2/abstract.
15. Theory of Mind cognitive model
The Theory of Mind (ToM) model suggests that people with 
ASDs have difficulty in understanding the minds (emotions, 
feelings, beliefs and thoughts) of other people. Interventions to 
teach ToM for patients could provide some benefits for ASDs. 
The review23 included 22 heterogeneous RCTs (695 partici-
pants). Evidence of some benefit was found for communication 
based on individual results (three RCTs; very low-quality evi-
dence), social interaction (11 RCTs; low-quality evidence), gen-
eral communication (4  RCTs; very low-quality evidence) and 
ToM ability (4 RCTs; very low-quality evidence). The meta-anal-
ysis showed that interventions targeting recognition of emotions 
across age groups and working with people within the average 
range of intellectual ability had a positive effect on the target skill 
(through a test using photographs of faces; mean increase = 0.75 
points; 95% CI = 0.22 to 1.29 points; four RCTs; 105 participants). 
It was found that therapist-led joint-attention approaches could 
improve joint attention behavior within adult-child interactions 
(mean increase = 0.55 points; 95% CI = 0.11 to 0.99 points; two 
RCTs; 88 participants). However, further analysis undermined 
this conclusion by demonstrating that there was no clear evi-
dence that intervention could improve joint-attention initiations 
as measured using a standardized assessment tool (mean increase 
= 0.23 points, 95% CI = -0.48 to 0.94 points; three RCTs; 92 par-
ticipants). No adverse effects were observed. 
The authors concluded that there was some evidence that teach-
ing ToM to people with ASD seemed to present benefits. However, 
inconsistencies in the findings and measurements meant that that 
the evidence was of very low or low quality, which reduced the con-
fidence in these findings. For further details, the original abstract 
can be consulted, available from: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD008785.pub2/abstract.
16. Tricyclic antidepressants
Because of the impact of tricyclic antidepressants (TCAs) on sero-
tonins, they have been used to treat ASDs. The review24 included 
three RCTs assessing clomipramine (two RCTs) or tianeptine 
(one RCT), for children and young adults with ASDs. Due to het-
erogeneity among the study participants, types of TCAs and out-
comes measured, no meta-analysis was performed. One study 
showed that tianeptine could be effective over the short term for 
reducing irritability, hyperactivity, inadequate eye contact and 
inappropriate speech, but clinician ratings found that it did not 
have any significant impact on these symptoms. There were also 
significant adverse effects, including increased drowsiness and 
reduced activity levels. For clomipramine, there was evidence 
of improvement in autistic symptoms, irritability and obsessive-
compulsive disorder symptoms. However, there was conflicting 
evidence in relation to hyperactivity across the two studies on 
clomipramine, and no significant changes were found regarding 
inappropriate speech. There were significant dropout rates in the 
clomipramine arm of one study. 
The authors concluded that since there was limited and conflict-
ing evidence regarding the effects and side effects of TCAs for this 
purpose, further research would be required before TCAs could be 
recommended for ASDs. For further details, the original abstract 
can be consulted, available from: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD008372.pub2/abstract. 
17. Vitamin B6 plus magnesium
The review25 included three small heterogeneous RCTs (33 par-
ticipants) and pooling the data was not possible. One RCT did 
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not report sufficient data to be analyzed. The second RCT did not 
find any significant differences between the treatment and pla-
cebo groups regarding social interactions, communication, com-
pulsivity, impulsivity or hyperactivity. The last RCT focused on 
a subgroup of children with pervasive developmental disorders 
(PDDs) who exhibited clinical features similar to those with pyr-
idoxine-dependent epilepsy. This small study (n = 8) only mea-
sured IQ and social quotient and found that there was a statisti-
cally significant benefit from vitamin B6 plus magnesium for IQ 
(MD = 5.2; 95% CI = 0.2 to 10.3). 
The authors concluded that due to the small number of studies, 
the methodological quality of studies and the small sample sizes, 
no recommendations could be made regarding use of vitamin B6 
plus magnesium for ASDs. For further details, the original abstract 
can be consulted, available from: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD003497.pub2/abstract.
DISCUSSION 
This review found that despite increasing prevalence of ASDs, there 
are still few systematic reviews and there is a scarcity of high-qual-
ity randomized trials addressing interventions for improving the 
main clinical features of ASDs. None of the reviews included here 
provided high-quality evidence for any outcome. Even more sur-
prisingly, some of the interventions studied do not have any proven 
pathophysiological link with the disease or any well-known poten-
tial therapeutic mechanism (such as gluten and casein-free diets, 
omega-3 fatty acids and chelating agents). Furthermore, many of 
the off-label interventions used present no benefit for patients and 
could also increase the risk of adverse events.
Overall, the primary studies from each of the systematic reviews 
included had limited methodological quality, small sample sizes, short-
term measurements of outcomes and poor reporting of adverse events. 
All of these facts increase the uncertainty surrounding the effects of 
the pharmacological and non-pharmacological interventions that are 
frequently used in clinical practice as options for patients with ASDs. 
Regarding the implications for practice, some non-pharma-
cological interventions seem to be useful, given that they pres-
ent some beneficial effects with few adverse events (albeit based 
on very low to low-quality evidence). These include gluten and 
casein-free diets, acupuncture, early intensive behavioral inter-
vention, music therapy, parent-mediated early intervention, 
social skill groups and the Theory of Mind cognitive model. 
Their use needs to be discussed with patients, parents and care-
givers in order to clarify the uncertainties regarding the results, 
time taken and costs.
Among the pharmacological options, aripiprazole, risperi-
done tricyclic antidepressants (clomipramine and tianeptine) and 
selective serotonin reuptake inhibitors (this last category only for 
adults) seem to have some benefits for specific symptoms, but the 
adverse events that have been reported need to be carefully con-
sidered before making decisions. 
Regarding the implications for further research, this review of 
reviews makes it clear that much needs to be done on the thera-
peutics of ASDs. Firstly, experimental research exploring physio-
pathological mechanisms needs to be conducted in order to sup-
port further clinical studies. Subsequently, good-quality long-term 
clinical trials are required.
CONCLUSION 
This review included 17 Cochrane systematic reviews. None of 
them provided high-quality evidence for any autism-related out-
come. Acupuncture, early intensive behavioral intervention, glu-
ten and casein-free diets, music therapy, parent-mediated early 
intervention, social skill groups and the Theory of Mind cogni-
tive model seem to have benefits for patients with autism spectrum 
disorders (very low to low-quality evidence). Aripiprazole, risperi-
done, clomipramine, tianeptine and selective serotonin reuptake 
inhibitors are pharmacological options that seem to have some 
benefits (this last one only for adults), but all of them are associated 
with high risks of important adverse events. Experimental research 
to confirm the links between therapeutic options and the disease is 
needed, followed by high-quality long-term clinical trials.
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